UMBF UMB delivers 52 percent Q4 2025 EPS beat but shares drop 113 percent in todays trading AbbVie Inc ABBV Submits SKYRIZI Subcutaneous Crohns Regimen to FDA But NearTerm Upside Remains Capped By Competitive Risks What high yield iShares ETHB